Answers are grounded in this paper and cite their sources.
Selenium, an essential micronutrient with a small therapeutic range, has proven to play a dual role in diabetes mellitus: it is not only a protective agent but also a possible risk factor, which depends on dosage, chemical form and physiological state. The present review is a synthesis of the available information on the molecular basis of the bidirectional impact of selenium on type 2 diabetes (T2DM) and emphasizes the central role played by it in redox homeostasis, insulin signaling, and the functional activity of β-cells. We explain the fact that physiological concentrations of selenium can enhance antioxidant protection and increase insulin sensitivity, including through the use of selenoproteins like GPXs and TXNRDs, whereas supra-nutritional exposure causes oxidative stress, insulin resistance, and dysglycemia, due to the actions of pro-oxidants and endoplasmic reticulum stress. In addition, we consider the newest findings on the relationship between selenium and gut microbiota and assess more sophisticated delivery systems, including nano-selenium and selenium-polysaccharide conjugates, that could reduce the risk of diabetes and be more effective in treatment. Nevertheless, in spite of the current debates and non-linear dose-response interactions recorded in epidemiological studies, it is evident that the advantages of selenium will only be achieved with accurate dosing and speciation. Future studies should focus on stratifying clinical trials and mechanistic studies to clarify context-specific effects, fine-tune selenium-based interventions, and develop personalized nutrition plans to prevent and manage diabetes.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: